Navigation Links
Southern Research Scientists to Present New Data at the American Association for Cancer Research 102nd Annual Meeting in Orlando
Date:3/29/2011

BIRMINGHAM., Ala., March 29, 2011 /PRNewswire-USNewswire/ -- Southern Research Institute, a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug discovery and drug development today announced that its scientists will be delivering 13 poster presentations at the AACR 102nd Annual Meeting 2011, April 2-6, in Orlando, Fla. Southern Research will also be available to meet with scientists at Booth #543.

Southern Research has discovered more than 20 anti-cancer drugs which have been accepted into clinical trials. Of those, seven have received FDA approval, with six additional drugs currently in late stage preclinical and early clinical trials. Further, Southern Research has evaluated 50 percent of all other FDA-approved cancer drugs on the market. Contract research services include basic research and target identification, lead discovery and optimization, preclinical development and clinical trials support.

Southern Research scientists will present new preclinical data posters in the Exhibit Hall:

Sunday April 3, 2011

1:00 p.m. – 5:00 p.m.

#837:  Novel sulindac derivatives that inhibit colon cancer growth by a cyclooxygenase-independent mechanism involving PDE5 inhibition and the suppression of nuclear Beta-catenin levels   (Exhibit Hall A4-C, Poster Section 34)

Monday April 4, 2011

8:00 a.m. – 12:00 p.m.

#1053:  Mouse Kremen 1 negatively regulates Wnt/Beta-catenin signaling in human breast cancer MDA-MB-231 cells   (Exhibit Hall A4-C, Poster Section 3)

#1853: PDE5 suppression selectively induces apoptosis of human breast tumor cells and attenuates Wnt/Beta-catenin mediated transcription   (Exhibit Hall A4-C, Poster Section 34)

#1865:  Colon cancer chemopreventive properties of a non-cyclooxygenase inhibitory amide derivative of sulindac   (Exhibit Hall A4-C, Poster Section 34)

1:00 p.m. – 5:00 p.m.

#2537:  Novel 2'-deoxycytidine analogs as DNA demethylation agents (Exhibit Hall A4-C, Poster Section 26)

Tuesday April 5, 2011

8:00 a.m. – 12:00 p.m.

#3114:  Effects of tumor-stromal interactions on gene expression in panel of mouse tumor models   (Exhibit Hall A4-C, Poster Section 11)

#3707:  Sulindac sulfide inhibits growth and induces apoptosis of human colon tumor cells by a cGMP-dependent pathway leading to suppression of Beta-catenin transcription activity (Exhibit Hall A4-C, Poster Section 34)

1:00 p.m. – 5:00 p.m.

#4418:  Affymetrix whole genome microarray analysis of 24 human tumor xenograft models and the cell lines from which they were developed: Clustering of targets vs tumor tissue of origin   (Exhibit Hall A4-C, Poster Section 24)

#4265: Bithionol as an inhibitor of tumor angiogenesis (Exhibit Hall A4-C, Poster Section 18)

#3943:  Affymetrix whole genome microarray analysis of 51 human tumor cell lines representative of 16 different tissues of origin: Unsupervised hierarchical clustering

(Exhibit Hall A4-C, Poster Section 6)

#4610:  NO-NSAIDs inhibit colon tumor cell growth by a cGMP-independent mechanism (Exhibit Hall A4-C, Poster Section 33)

Wednesday April 6, 2011

8:00 a.m. – 12:00 p.m.

#5443:  A novel biosensor for monitoring intracellular cGMP in live cells (Exhibit Hall A4-C, Poster Section 29)

#5154: Serotonin signaling as a novel target of tumor angiogenesis (Exhibit Hall A4-C, Poster Section 18)

Southern Research will also have members of its new preclinical, non-invasive imaging team at Booth #543 on hand to discuss this new service.

ABOUT SOUTHERN RESEARCH

Southern Research Institute, founded in 1941, is an independent non-profit organization conducting basic and applied research and development.  More than 530 employees support commercial and government clients and partners in the pharmaceutical, biotechnology, defense, aerospace, environmental and energy sectors through technology out-licensing, sponsored research, and strategic collaborations.  Headquartered in Birmingham, Ala., Southern Research has facilities in Wilsonville, Ala., Frederick, Md., and Durham, NC and offices in Huntsville, Ala., New Orleans, La., Washington, DC and Kiev, Ukraine. For more information about our capabilities, contact us by email at BusDev@SouthernResearch.org or call 888-322-1166 (U.S.) or 1-205-581-2830 (International.)

Contact: Rhonda Jung
205-337-9634
Jung@SouthernResearch.org


'/>"/>
SOURCE Southern Research Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Southern Home Medical Equipment Appoints Jerry Overcash to the Board of Directors
2. Southern Home Medical Equipment Engages Northern Virginia Based Waterford Holdings Group to Evaluate and Consider Acquisition Candidates in the Mid-Atlantic Area
3. Encinitas Nursing and Rehabilitation Center First in Southern California to Deploy Voice Technology for Outcomes-Based Care
4. MinuteClinic and St. Rose Dominican Hospitals Form Clinical Collaboration to Improve Access to Health Care in Southern Nevada
5. BioSpace Showcases Southern Californias Growing Life Science Region
6. Southern Research Announces Completion of $20 Million Bond Transaction
7. Southern California Cell Company Partners With Northern California Life Science Research Technology Company for Developing Human Derived Disease Specific iPS Cell Lines
8. Pro Medicus/Visage Imaging Signs Deal with Sydney-based Southern Radiology
9. Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture
10. Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California
11. Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... 2016  Results from the Phase II SUSTAIN study ... reduced the median annual rate of sickle cell-related pain ... 2.98, p=0.010) in patients with or without hydroxyurea therapy ... being featured in the official press briefing at the ... Meeting and presented during the Plenary Scientific Session tomorrow ...
(Date:12/2/2016)... December 2, 2016 - bioLytical lanza el INSTI HIV ... la OMS     Continue Reading ... ... , , bioLytical ... anunciado hoy que está expandiendo el lanzamiento de su INSTI HIV Self Test ...
(Date:12/2/2016)... December 2, 2016 According to the ... Market Study on Automated Endoscope Reprocessors: Single Basin Automated Endoscope ... 8.6% Between 2016 and 2024 " the global automated endoscope reprocessors market was ... to expand at a CAGR of 7.2% during an eight-year ... 1,367.6 Mn by 2024. ...
Breaking Medicine Technology:
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish to ... advantage of a cosmetic procedure known as Carbon Dioxide (C02) Fractional Laser ... of age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity or ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... will speak at the American Conference Institute’s 21st Drug & Medical Device Litigation ... Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than 100 business, civic, ... to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This inaugural event, ... and operating support to UNCF-member institutions, including Miles College, Oakwood University, Tuskegee University, ...
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
Breaking Medicine News(10 mins):